In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.
Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of relapsed or refractory Waldenström macroglobulinemia; evaluation and management of aggressive transformation in Waldenström macroglobulinemia; management of Waldenström macroglobulinemia in limited-resource settings; and more.
Provides in-depth clinical reviews of Waldenström macroglobulinemia, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia - p. 659 9. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy - p. 671 10. Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia - p. 689 11. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia - p. 707 12. Future Directions in the Frontline Management of Waldenström Macroglobulinemia - p. 719 13. The Management of Relapsed or Refractory Waldenström’s Macroglobulinemia - p. 727 14. Novel Agents in Waldenström Macroglobulinemia - p. 751 15. Investigation and Management of Immunoglobulin M– and Waldenström-Associated Peripheral Neuropathies - p. 761 16. Evaluation and Management of Bing–Neel Syndrome - p. 777 17. Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia - p. 787 18. Management of Waldenström Macroglobulinemia in Limited-Resource Settings - p. 801
In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.
Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenström macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenström macroglobulinemia; management of relapsed or refractory Waldenström macroglobulinemia; evaluation and management of aggressive transformation in Waldenström macroglobulinemia; management of Waldenström macroglobulinemia in limited-resource settings; and more.
Provides in-depth clinical reviews of Waldenström macroglobulinemia, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia - p. 659 9. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy - p. 671 10. Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia - p. 689 11. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia - p. 707 12. Future Directions in the Frontline Management of Waldenström Macroglobulinemia - p. 719 13. The Management of Relapsed or Refractory Waldenström’s Macroglobulinemia - p. 727 14. Novel Agents in Waldenström Macroglobulinemia - p. 751 15. Investigation and Management of Immunoglobulin M– and Waldenström-Associated Peripheral Neuropathies - p. 761 16. Evaluation and Management of Bing–Neel Syndrome - p. 777 17. Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia - p. 787 18. Management of Waldenström Macroglobulinemia in Limited-Resource Settings - p. 801
